Porton Fine Chemicals Ltd.

The company was founded in 2005 and mainly provides one-stop customized R&D and production services for small molecule drugs, peptides and oligonucleotides, biomacromolecules (mAbs, ADCs, etc.), and gene and cell therapy drugs required for the entire life cycle from pre-clinical research to drug marketing. The company is a pharmaceutical R&D and manufacturing outsourcing organization (CDMO) that provides a full range of end-to-end services to pharmaceutical companies, biotechnology companies, scientific research institutions, etc. on a global scale. It can provide CDMO services for various types of drugs and therapies such as small molecule drugs, large molecule drugs, and gene cell therapy. The company's products include small molecule drug CDMO business, small molecule formulation CDMO business, gene cell therapy CDMO business, synthetic macromolecule and biomacromolecule CDMO business (TIDES, ADC). During the reporting period, the company won titles such as “2022 Chongqing Top 100 Private Enterprises”, “Chongqing Digital Workshop”, “Chongqing Innovation Demonstration Smart Factory”, “Environmental Integrity Enterprise”, “Excellent Practice Case of Listed Company's 2021 Report Performance Briefing”, and “2022 Extraordinary Employer Award”. The subsidiary Jiangxi Boten won “2022 Advanced Grassroots Party Organization”, “2021 Advanced Enterprise for Green Development”, and “Top 10 Companies with Tax Contribution in 2021”; the subsidiary Boteng Biotech won “2022 Most Promising Employer for Development”,” “2022 Top 10 Most Growing CXO Companies”, won customer honors such as Zhimeng Pharmaceutical's “Outstanding Partner Award”, and Xingsheng Xinhui's “Best Partner”.